[go: up one dir, main page]

BRPI0416981A - compostos para tratamento de doenças proliferativas de célula - Google Patents

compostos para tratamento de doenças proliferativas de célula

Info

Publication number
BRPI0416981A
BRPI0416981A BRPI0416981-6A BRPI0416981A BRPI0416981A BR PI0416981 A BRPI0416981 A BR PI0416981A BR PI0416981 A BRPI0416981 A BR PI0416981A BR PI0416981 A BRPI0416981 A BR PI0416981A
Authority
BR
Brazil
Prior art keywords
compounds
cell proliferative
proliferative diseases
treating cell
present
Prior art date
Application number
BRPI0416981-6A
Other languages
English (en)
Inventor
Waldemar Priebe
Nicholas Donato
Moshe Talpaz
Alexander Levitzki
Izabela Fokt
Slawomir Szymanski
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BRPI0416981A publication Critical patent/BRPI0416981A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS PARA TRATAMENTO DE DOENçAS PROLIFERATIVAS DE CéLULA. A presente invenção refere-se a compostos e seu uso para tratar doenças de célula proliferativa tal como câncer. Os compostos da presente invenção mostram potência significante como inibidores de cinase, causam a sub-regulatem de c-myc e inibem o crescimento e sobrevivência de tipos de célula cancerosa.
BRPI0416981-6A 2003-12-11 2004-12-13 compostos para tratamento de doenças proliferativas de célula BRPI0416981A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52887703P 2003-12-11 2003-12-11
PCT/US2004/041712 WO2005058829A1 (en) 2003-12-11 2004-12-13 Compounds for treatment of cell proliferative diseases

Publications (1)

Publication Number Publication Date
BRPI0416981A true BRPI0416981A (pt) 2007-02-21

Family

ID=34699909

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416981-6A BRPI0416981A (pt) 2003-12-11 2004-12-13 compostos para tratamento de doenças proliferativas de célula

Country Status (17)

Country Link
US (4) US7745468B2 (pt)
EP (2) EP2487156B1 (pt)
JP (1) JP4751336B2 (pt)
KR (2) KR101170655B1 (pt)
CN (2) CN1894215B (pt)
AU (1) AU2004298511B2 (pt)
BR (1) BRPI0416981A (pt)
CA (1) CA2548152C (pt)
DK (1) DK1701941T3 (pt)
ES (1) ES2385831T3 (pt)
IL (1) IL176028A (pt)
MX (1) MXPA06006460A (pt)
PL (1) PL1701941T3 (pt)
PT (1) PT1701941E (pt)
SI (1) SI1701941T1 (pt)
WO (1) WO2005058829A1 (pt)
ZA (1) ZA200604682B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1894215B (zh) 2003-12-11 2012-03-21 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
JP2009511562A (ja) * 2005-10-13 2009-03-19 オーキッド リサーチ ラボラトリーズ リミティド ｐＳＴＡＴ３／ＩＬ−６インヒビターとしての新規ヘテロ環式化合物
AU2007234455B2 (en) * 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20100292229A1 (en) * 2006-06-30 2010-11-18 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
CA2668652C (en) 2006-11-20 2018-06-12 President And Fellows Of Harvard College Inhibitors of voltage-gated ion channels for use in treating pain and pruritis
US20080167277A1 (en) * 2006-12-29 2008-07-10 Charles Conrad Methods of treating skin disorders with caffeic acid analogs
WO2008121858A1 (en) * 2007-03-28 2008-10-09 Board Of Regents, The University Of Texas System Small molecule inhibitors for immune modulation
CA2736564A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
WO2010005807A2 (en) * 2008-07-08 2010-01-14 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
JP6013735B2 (ja) 2008-09-30 2016-10-25 マリンクロット ニュークリア メディシン エルエルシー 画像目的のためのヘキソースおよび金属配位結合化合物の結合体
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
WO2010081158A2 (en) * 2009-01-12 2010-07-15 The Board Of Regents Of The University Of Texas System Blood test for the detection of cancer
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
MX2012004363A (es) 2009-10-16 2012-05-22 Bayer Cropscience Ag Aminopropenoatos como fungicidas.
EP2506852A4 (en) 2009-12-04 2013-06-19 Univ Texas INTERFERONTHERAPIES IN COMBINATION WITH BLOCKING OF STAT3 ACTIVATION
WO2011097522A2 (en) * 2010-02-05 2011-08-11 Whitehead Institute For Biomedical Research Combination methods for treatment of disease
JP2013522326A (ja) 2010-03-19 2013-06-13 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の方法
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
EP2510787A1 (en) 2011-04-15 2012-10-17 Bayer Cropscience AG Propenoates as fungicides
WO2012165262A1 (ja) 2011-05-27 2012-12-06 国立大学法人徳島大学 ベンジルアミン誘導体
WO2013009872A1 (en) 2011-07-11 2013-01-17 The Regents Of The University Of Michigan Multimodality left atrial appendage occlusion device
JP6290871B2 (ja) * 2012-05-25 2018-03-07 ザ ガヴァーニング カウンシル オブ ザ ユニヴァーシティ オブ トロント 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
WO2014039908A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US20160367627A1 (en) 2013-07-02 2016-12-22 Nikolai Khodarev Anti-tumor therapy
JP2016537316A (ja) * 2013-10-10 2016-12-01 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP6833811B2 (ja) 2015-08-03 2021-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 荷電イオンチャネル遮断薬及び使用方法
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
TWI846678B (zh) 2017-11-10 2024-07-01 美國德州系統大學評議委員會 咖啡酸衍生物及其用途
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
SG11202109713PA (en) 2019-03-11 2021-10-28 Nocion Therapeutics Inc Ester substituted ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN113811305A (zh) 2019-03-11 2021-12-17 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
IL286172B1 (en) 2019-03-11 2025-10-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
JP2022520287A (ja) * 2019-04-02 2022-03-29 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 疾患の治療のための転写インヒビターと免疫チェックポイントインヒビターの組み合わせ
MX2021012216A (es) 2019-04-05 2022-01-24 Kymera Therapeutics Inc Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
IL292505A (en) 2019-11-06 2022-06-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
CA3155568A1 (en) 2019-11-06 2021-05-14 Bridget Mccarthy Cole Charged ion channel blockers and methods for use
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2021183639A1 (en) 2020-03-11 2021-09-16 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN115381822A (zh) * 2022-05-11 2022-11-25 暨南大学附属第一医院（广州华侨医院） 一种基于激活免疫应答治疗肺癌的药物及制药应用
KR102811597B1 (ko) * 2022-06-22 2025-05-22 한국생명공학연구원 신규한 신남아마이드 유도체 및 이의 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555789A1 (de) 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
FR2629455B1 (fr) * 1988-03-29 1991-09-27 Rhone Poulenc Agrochimie Derives de 2-(3-pyridinyl)3-(phenoxy) propanenitrile
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
EP0527181A4 (en) 1990-04-16 1993-04-07 Rorer International (Holdings) Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
CA2092017A1 (en) 1992-03-26 1993-09-27 Tameo Iwasaki Butadiene derivatives and process for preparing the same
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH06247850A (ja) 1993-02-24 1994-09-06 Suntory Ltd １２−リポキシゲナーゼ阻害剤
US5823706A (en) 1993-07-27 1998-10-20 The University Of Birmingham Pavements
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
IL107736A (en) 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
WO1995028922A1 (en) 1994-04-22 1995-11-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of benzylidene-malononitrile derivates for the treatment of leukemia
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US5854285A (en) * 1997-04-03 1998-12-29 Natpro, Inc. Protein kinase inhibitor
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
US6313153B1 (en) 1997-07-25 2001-11-06 Tsumura & Co. Compositions and methods for treating nephritis and inhibiting TGF -β related conditions using pyridylacrylamide derivatives
US6225346B1 (en) * 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
KR100674760B1 (ko) * 1999-03-04 2007-01-25 리가가쿠 겐큐쇼 촉매 조성물
US20020045191A1 (en) * 2000-09-15 2002-04-18 Schneider Robert J. Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
JP2003119169A (ja) 2001-07-30 2003-04-23 Shigetoshi Kadota 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
KR100944174B1 (ko) 2001-11-30 2010-02-24 산텐 세이야꾸 가부시키가이샤 혈관 신생 저해제
WO2003068157A2 (en) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
WO2004047743A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
KR20050055479A (ko) 2003-12-08 2005-06-13 김철호 카페인산 또는 카페인산 페네틸에스테르를 유효성분으로하는 ｍｍｐ-9 억제제
CN1894215B (zh) * 2003-12-11 2012-03-21 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
AU2007234455B2 (en) * 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20100292229A1 (en) 2006-06-30 2010-11-18 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
WO2008053297A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa

Also Published As

Publication number Publication date
CN102603565A (zh) 2012-07-25
KR101218633B1 (ko) 2013-01-09
HK1094891A1 (en) 2007-04-13
US7745468B2 (en) 2010-06-29
WO2005058829A1 (en) 2005-06-30
CN1894215A (zh) 2007-01-10
PL1701941T3 (pl) 2012-11-30
IL176028A (en) 2012-05-31
CN1894215B (zh) 2012-03-21
SI1701941T1 (sl) 2012-09-28
US8648102B2 (en) 2014-02-11
US20120214850A1 (en) 2012-08-23
CA2548152C (en) 2013-09-10
EP2487156B1 (en) 2014-07-16
US8119827B2 (en) 2012-02-21
ZA200604682B (en) 2008-04-30
KR101170655B1 (ko) 2012-08-03
EP2487156A1 (en) 2012-08-15
AU2004298511B2 (en) 2011-08-11
EP1701941A1 (en) 2006-09-20
KR20070000428A (ko) 2007-01-02
EP1701941A4 (en) 2008-11-12
US20050277680A1 (en) 2005-12-15
US9096499B2 (en) 2015-08-04
AU2004298511A1 (en) 2005-06-30
DK1701941T3 (da) 2012-08-13
CA2548152A1 (en) 2005-06-30
KR20110132489A (ko) 2011-12-07
IL176028A0 (en) 2006-10-05
MXPA06006460A (es) 2006-08-23
PT1701941E (pt) 2012-08-03
ES2385831T3 (es) 2012-08-01
JP4751336B2 (ja) 2011-08-17
JP2007515413A (ja) 2007-06-14
US20110021805A1 (en) 2011-01-27
EP1701941B1 (en) 2012-05-30
US20140329901A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
ECSP066362A (es) Inhibidores de quinesina mitótica.
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
ECSP109934A (es) Compuesto - 946
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
UY28271A1 (es) Compuestos químicos
CL2004001359A1 (es) Compuestos derivados de piperazina, composicion farmaceutica, utiles como agentes inhibidores de polimerizacion de la tubulina, inhibidores de celulas tumorales y para tratar cancer.
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
MX2024002261A (es) Molecula de union de fap/cd40 y uso medicinal de la misma.
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
CR20240447A (es) Compuestos de urea tricíclica como inhibidores de v617f de jak2.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]